See more : LexaGene Holdings Inc. (LXXGF) Income Statement Analysis – Financial Results
Complete financial analysis of CAD/JPY (HSIL.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CAD/JPY, a leading company in the Medical – Specialties industry within the Healthcare sector.
You may be interested
- Cellnet Group Limited (CLT.AX) Income Statement Analysis – Financial Results
- Jiangsu King’s Luck Brewery Joint-Stock Co., Ltd. (603369.SS) Income Statement Analysis – Financial Results
- Allgeier SE (AEIN.DE) Income Statement Analysis – Financial Results
- LEATEC Fine Ceramics Co., Ltd. (6127.TWO) Income Statement Analysis – Financial Results
- Edwards Lifesciences Corporation (EW) Income Statement Analysis – Financial Results
CAD/JPY (HSIL.BO)
About CAD/JPY
Hemant Surgical Industries Ltd. operates as a pharmaceutical company. It engages in the importing, manufacturing & marketing surgical and pharmaceutical products. The company was founded by Hanskumar Shamji Shah in 1985 and is headquartered in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.06B | 1.09B | 1.04B | 597.65M | 562.35M |
| Cost of Revenue | 867.94M | 893.81M | 901.39M | 524.72M | 482.80M |
| Gross Profit | 188.14M | 197.68M | 134.31M | 72.93M | 79.55M |
| Gross Profit Ratio | 17.81% | 18.11% | 12.97% | 12.20% | 14.15% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 90.90M | 95.41M | 84.07M | 43.75M | 49.54M |
| Other Expenses | -213.00K | -4.20M | -2.94M | 0.00 | 0.00 |
| Operating Expenses | 91.11M | 99.62M | 87.01M | 43.75M | 49.54M |
| Cost & Expenses | 959.05M | 993.42M | 988.40M | 568.47M | 532.33M |
| Interest Income | 0.00 | 5.24M | 1.24M | 1.58M | 1.17M |
| Interest Expense | 9.72M | 19.89M | 34.53M | 18.07M | 16.03M |
| Depreciation & Amortization | 10.26M | 8.50M | 13.40M | 6.34M | 4.95M |
| EBITDA | 147.80M | 106.56M | 60.70M | 35.52M | 34.96M |
| EBITDA Ratio | 13.99% | 9.76% | 5.86% | 5.94% | 6.22% |
| Operating Income | 94.44M | 98.06M | 47.30M | 29.18M | 30.02M |
| Operating Income Ratio | 8.94% | 8.98% | 4.57% | 4.88% | 5.34% |
| Total Other Income/Expenses | 33.37M | 2.51M | -13.33M | -13.97M | -21.47M |
| Income Before Tax | 127.81M | 100.57M | 33.97M | 15.20M | 8.55M |
| Income Before Tax Ratio | 12.10% | 9.21% | 3.28% | 2.54% | 1.52% |
| Income Tax Expense | 29.81M | 24.20M | 6.80M | 3.75M | 3.53M |
| Net Income | 98.00M | 76.37M | 27.17M | 11.45M | 5.01M |
| Net Income Ratio | 9.28% | 7.00% | 2.62% | 1.92% | 0.89% |
| EPS | 10.37 | 9.94 | 2.60 | 1.10 | 0.48 |
| EPS Diluted | 10.37 | 9.94 | 2.60 | 1.10 | 0.48 |
| Weighted Avg Shares Out | 9.45M | 7.68M | 10.44M | 10.44M | 10.44M |
| Weighted Avg Shares Out (Dil) | 9.45M | 7.68M | 10.44M | 10.44M | 10.44M |
No news found for: HSIL.BO
Source: https://incomestatements.info
Category: Stock Reports